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Our present cases exhibiting these
complex mutations suggest the intratu-
moral heterogeneity of EGFR mutations.
Considering intratumoral heterogene-
ity consisting of EGFR-sensitive-mutated
cells and wild-type or EGFR-resistant-
mutated cells, the detection of EGFR mu-
tations using a highly sensitive polymer-
ase chain reaction method from small
biopsies may not always reflect whole
tumor sensitivity to EGFR-TKIs.4 How-
ever, our data were taken from only a few
cases, and further research is needed. The
clinical significance of intratumoral heter-
ogeneity warrants future studies.
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To the Editor:
On March 2010, because of a wors-
ening in his breathing ability, a heavy
smoking (40 pack/yr) 54-year-old man
performed a chest computed tomogra-
phy, which showed a left-sided pleural
effusion. A thoracoscopy showed multi-
ple pleural nodules, which were biop-
sied. The diagnosis was pleural metas-
tases from lung adenocarcinoma. The
percentage of tumor cells in the pleural
bioptical specimen was 60. The tumor
did not harbor neither the epidermal
growth factor receptor nor K-ras muta-
tions. Six cycles of cisplatin plus pem-
etrexed were administered with a partial
response. On November 2010, he re-
ceived a laparoscopy diagnosing perito-
neal metastases from lung adenocarci-
noma. The percentage of tumor cells in
the peritoneal bioptical specimen was
70. Sanger bidirectional sequencing did
not show epidermal growth factor recep-
tor and K-ras mutations. Two cycles of
gemcitabine plus docetaxel were admin-
istered with a progressive disease. On
December 2010, the presence of EML4-
ALK gene fusion was investigated. The
fluorescent in situ hybridization test was
performed on formalin-fixed and paraf-
fin-embedded tissue samples by using a
break-apart probe to ALK (ALK Dual
Color Probe of Vysis, Inc., Downers
Grove, IL). According to the score pro-
posed by Kwak et al.,1 the test was
considered negative in the pleural bi-
opsy (4% of the neoplastic cells with
split of the 5 and 3 probe signals),
whereas it was positive in the peritoneal
sample (15% of the scored tumor cells
had split of the 5 and 3 probe signals or
had isolated 3 signals). Unfortunately,
because of a rapid deterioration of the
clinical conditions, the patient was un-
able to receive any further therapy and
died on January 2011.
The EML4-ALK fusion gene pos-
sesses a potent oncogenic activity both
in vitro and in vivo and is detected in
approximately 3 to 5% of non-small cell
lung cancer, predominantly in patients
with adenocarcinoma and no or minimal
smoking history.1,2 These patients were
also found to be less responsive to plat-
inum-based chemotherapy and to have a
lower overall survival.3 Crizotinib, an
inhibitor of the tyrosine kinase activity
of both ALK and the met proto-oncogene,
demonstrated high activity in these pa-
tients.1 To the best of our knowledge, this
is the first report concerning a discrep-
ancy of the EML4-ALK gene detection
between primary and corresponding me-
tastases. The molecular basis for this
disparity is not known, but the evidence
of tumultuous growth in disease evolu-
tion might be related to a rapid change in
tumor biology. In our case, the EML4-
ALK fluorescent in situ hybridization
positivity was detected in a heavy smoker,
not a frequently characteristic, and the
onset of peritoneal metastasis, positive
for the EML4-ALK fusion gene, corre-
sponded to a worsening of prognosis as
expected. These observations may have
important clinical implications for the
molecular testing of targeted therapies,
calling for a much better selection of
patients and for the availability of met-
astatic tissue for the detection of the
presence of specific target to better ad-
dress the treatment.
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